SNY vs. PFE, BMY, NVS, BIIB, AZN, GSK, MRNA, TAK, TEVA, and BGNE
Should you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Pfizer (PFE), Bristol-Myers Squibb (BMY), Novartis (NVS), Biogen (BIIB), AstraZeneca (AZN), GSK (GSK), Moderna (MRNA), Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), and BeiGene (BGNE). These companies are all part of the "medical" sector.
Pfizer (NYSE:PFE) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings, institutional ownership and community ranking.
Pfizer received 1458 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 69.07% of users gave Pfizer an outperform vote while only 53.97% of users gave Sanofi an outperform vote.
Pfizer currently has a consensus price target of $34.50, indicating a potential upside of 12.12%. Sanofi has a consensus price target of $57.50, indicating a potential upside of 9.73%. Given Sanofi's higher possible upside, research analysts plainly believe Pfizer is more favorable than Sanofi.
Pfizer has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.
Pfizer pays an annual dividend of $1.68 per share and has a dividend yield of 5.5%. Sanofi pays an annual dividend of $1.47 per share and has a dividend yield of 2.8%. Pfizer pays out -2,799.5% of its earnings in the form of a dividend. Sanofi pays out 73.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 15 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
68.4% of Pfizer shares are owned by institutional investors. Comparatively, 10.0% of Sanofi shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Sanofi has lower revenue, but higher earnings than Pfizer. Pfizer is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.
Sanofi has a net margin of 10.52% compared to Sanofi's net margin of -0.56%. Pfizer's return on equity of 26.25% beat Sanofi's return on equity.
In the previous week, Pfizer had 28 more articles in the media than Sanofi. MarketBeat recorded 48 mentions for Pfizer and 20 mentions for Sanofi. Sanofi's average media sentiment score of 0.65 beat Pfizer's score of 0.62 indicating that Pfizer is being referred to more favorably in the media.
Summary
Pfizer beats Sanofi on 13 of the 21 factors compared between the two stocks.
Get Sanofi News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
Free SNY Stock Alerts